Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia

NCT00299702 · clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
355
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Collaborators